DSpace

DSpace at RU >    University Library >    Academic bibliography >

SFX Query

Files in This Item:

File Description SizeFormat
publisher's version361.92 kBAdobe PDFUnder Embargo

Title: Arts syndrome is caused by loss-of-function mutations in PRPS1
Author(s): Brouwer, A.P.M. de (236446894)
Williams, K.L.
Duley, J.A.
Kuilenburg, A.B.P. van
Nabuurs, S.B. (291535941)
Egmont-Peterson, M. (298983133)
Lugtenberg, D. (29897987X)
Zoetekouw, L.
Banning, M.J.G. (314085610)
Roeffen, M.
Hamel, B.C.J. (079063632)
Weaving, L.
Ouvrier, R.A.
Donald, J.A.
Wevers, R.A. (068311508)
Christodoulou, J.
Bokhoven, J.H.L.M. van (11529077X)
Publication year: 2007
Document type: Article / Letter to editor
Journal: American journal of human genetics
ISSN: 0002-9297
Volume: vol. 81
Issue: iss. 3
Start page: p. 507
End page: p. 518
Abstract: Arts syndrome is an X-linked disorder characterized by mental retardation, early-onset hypotonia, ataxia, delayed motor development, hearing impairment, and optic atrophy. Linkage analysis in a Dutch family and an Australian family suggested that the candidate gene maps to Xq22.1-q24. Oligonucleotide microarray expression profiling of fibroblasts from two probands of the Dutch family revealed reduced expression levels of the phosphoribosyl pyrophosphate synthetase 1 gene (PRPS1). Subsequent sequencing of PRPS1 led to the identification of two different missense mutations, c.455T-->C (p.L152P) in the Dutch family and c.398A-->C (p.Q133P) in the Australian family. Both mutations result in a loss of phosphoribosyl pyrophosphate synthetase 1 activity, as was shown in silico by molecular modeling and was shown in vitro by phosphoribosyl pyrophosphate synthetase activity assays in erythrocytes and fibroblasts from patients. This is in contrast to the gain-of-function mutations in PRPS1 that were identified previously in PRPS-related gout. The loss-of-function mutations of PRPS1 likely result in impaired purine biosynthesis, which is supported by the undetectable hypoxanthine in urine and the reduced uric acid levels in serum from patients. To replenish low levels of purines, treatment with S-adenosylmethionine theoretically could have therapeutic efficacy, and a clinical trial involving the two affected Australian brothers is currently underway.
Subject: UMCN 3.1: Neuromuscular development and genetic disorders
UMCN 5.1: Genetic defects of metabolism
Organization: Human Genetics
UMCN Extern
Bioinformatics
Neurology
Appears in Collections:Academic bibliography

Please use this identifier to cite or link to this item: http://hdl.handle.net/2066/35096

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

 

  DSpace Software Copyright © 2002-2011  Duraspace - Feedback